Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Low-Dose Acyclovir Recommended for HSV Prophylaxis in Leukemic Patients

November 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 11
Volume 4
Issue 11

SAN FRANCISCO-Low-dose intravenous acyclovir (Zovirax) provides effective prophylaxis against Herpes simplex virus (HSV) infection or reactivation in leukemic patients undergoing intensive chemotherapy, Carole Miller, MD, said at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

SAN FRANCISCO-Low-dose intravenous acyclovir (Zovirax) provideseffective prophylaxis against Herpes simplex virus (HSV)infection or reactivation in leukemic patients undergoing intensivechemotherapy, Carole Miller, MD, said at the 35th InterscienceConference on Antimicrobial Agents and Chemotherapy (ICAAC).

Furthermore, using IV acyclovir at dosages as low as 62.5 mg/m²every 4 hours results in a 50% decrease in drug cost over standarddosing, and the technique of administration does not increasenursing time, said Dr. Miller, assistant professor of oncology,Johns Hopkins University.

Until the advent of acyclovir, HSV infections were a significantcause of morbidity in patients undergoing intensive high-dosechemotherapy for leukemia, Dr. Miller pointed out.

About a decade ago, the effect of acyclovir as a prophylacticagent against reactivation of HSV was assessed at Johns Hopkinsin a randomized, double-blind, placebo-controlled study. In thisearlier trial, 73% of the placebo group developed culture-positiveHSV infection from a mucocutaneous lesion, while none in the prophylaxedgroup became positive.

To determine a minimal effective dose and schedule of acyclovirfor preventing HSV infection or reactivation, three studies wereset up, Dr. Miller said.

Overall, 517 persons with leukemia (AML-76%, ALL-16%, CML-8%)undergoing intensive chemotherapy received 1,000 courses of prophylacticacy-clovir with three consecutive regimens: 250 mg/m² q8hfor 309 courses; 125 mg/m² q6h for 225 courses; and 62.5mg/m² q4h for 466 courses. The median duration of prophylaxiswas 36.9 days (the median duration of bone marrow aplasia).

Patients were evaluable if they received a minimum of 7 days ofacyclovir prophylaxis, as well as having all negative surveillancecultures (throat, urine, blood) pre-acyclovir and within the first72 hours of beginning prophylaxis.

Only Two Failures

Skin and oral exams were carried out daily, and oral viral culturesfor HSV were done every week or if clinically indicated. A failurewas defined as a positive culture with or without lesions. Orallesions without a positive culture were not considered failures,as oral mucositis is common with intensive chemotherapy.

Of the 1,000 courses of acyclovir prophylaxis, Dr. Miller said,998 had no evidence of HSV infection or reactivation. Only twofailures were seen, both occurring in the 250 mg/m² every8 hours arm.

Dr. Miller said that 99 of 1,000 courses of acyclovir requireddose reduction for renal insufficiency. Also, in 28 of 1,000 courses,the dose of acyclovir was increased due to severe mucositis. Interestingly,this was done at the doctors' request and was not, in any of thecases, related to viral culture.

Articles in this issue

Managed Care Compels Evaluations of Cost Effectiveness
FDA Panel Recommends Approval of Breast Cancer Drugs
Total Outpatient Program Cuts Transplant Cost
DNA Repair Enzyme Decreases Skin Cancer Incidence in Animals
Notion of 'Global' Microbial Resistance May Be Oversimplified
Outpatient Oral Antibiotics Safe, Effective
Despite New Therapies, Malignant Pleural Mesothelioma Outcomes Are Not Improved
Casodex Available for Advanced Prostate Cancer
Use of Clarithromycin Prophylaxis Reduces MAC Infection, Mortality in Advanced AIDS Patients
Low-Dose Acyclovir Recommended for HSV Prophylaxis in Leukemic Patients
Vpr Gene Linked to HIV Immune Dysfunction
Study Shows Outpatient Chemotherapy Less Expensive Than Home Health Care Delivery
Extended Triple Antiretroviral Therapy Maintains Superiority
Amphotericin B Lipid Complex Effective, Less Toxic
African-Americans Are Target of Prostate Ca Education Efforts

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
5 experts are featured in this series
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.